N/A
N=1,800
Mobile Health Intervention to Increase HIV Testing and Linkage to Care
HIV
Bottom Line
View on ClinicalTrials.gov: NCT05484895 ↗Enrolled (actual)
1,800
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcome: Primary: Number of Participants Completing HIV Self-Testing — 878; 889; 857; 875 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- WeTest-WeLink (Behavioral); Control condition (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Male
- Sponsor
- Emory University
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Completing HIV Self-Testing |
878; 889; 857; 875; 837; 836 | — |
| SECONDARY Number of Participants With HIV Laboratory Test Results |
3; 6; 6; 5; 3; 5 | — |
| SECONDARY Number of Participants Attending Initial HIV Care Appointment |
3; 6; 6; 5; 3; 5 | — |
| SECONDARY Number of Participants Receiving Receipt of HIV Confirmatory Test |
3; 6; 6; 5; 3; 5 | — |
Summary
This 5-year project will test an mobile health approach to improve HIV self-testing (HST) and linkage to HIV-related care among high-risk men in China. HIV-negative men who have sex with men (MSM) will be randomly assigned to an intervention group: access to WeTest-WeLink (a mobile application-based HIV testing health promotion and risk reduction program), or a control group. Participant HST and sexual risk behaviors will be evaluated at baseline and at 6, 12, and 18 months post-baseline.
Eligibility Criteria
Inclusion Criteria
- 18 years or older
- Chinese
- Cis-gender male
- Condomless anal sex with another man in the past 6 months
- Resident in the study location for at least 6 months and no desire to relocate during the study period
- In possession of a mobile "smart" phone with capability to download and use WeChat
- HIV-negative (verified through HIV self-test at enrollment)
- Able to give informed consent
Exclusion Criteria
- HIV positive at enrollment
- Self-report coercion to participate
Data sourced from ClinicalTrials.gov (NCT05484895). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.